Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Continues Busy Year With Perrigo Offer

This article was originally published in The Pink Sheet Daily

Executive Summary

Still integrating businesses gained from Abbott and Famy Care, Mylan proposes a $205-per-share bid for Perrigo, which itself just closed a $4.5 billion takeout of Omega Pharma.

You may also be interested in...



Perrigo’s Irish Move Sets Stage For International Boost, Net Revenue Gain

OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.

US FDA Cosmetics Director Lists Talc, Formaldehyde In Hair Smoothers Among Priorities

Linda Katz, director of the FDA’s Office of Cosmetics and Colors, touched on cosmetics modernization legislation in her 21 September presentation on agency priorities at the Independent Beauty Association’s virtual FDA Cosmetics Regulations Workshop.

PFAS Remain High Priority For US FDA’s Cosmetics Office – Director Linda Katz

“We’ve been keeping tabs of the amount of products containing PFAS over the last several years and, unfortunately, we’re not seeing really a lot of it going away,” said Katz, director of the Office of Cosmetics and Colors, at the Independent Beauty Association’s Cosmetics Regulations Workshop.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS078452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel